【摘要】 目的 探讨甲磺酸伏美替尼片（简称“伏美替尼”）引起心力衰竭的临床表现、发生机制及治疗策略。方法 分析1例肺癌晚期的女性患者接受第三代表皮生长因子受体-酪氨酸激酶抑制剂（伏美替尼）后出现心力衰竭，结合文献讨论其潜在发病机制和治疗措施。结果 患者服用伏美替尼3个月后出现心力衰竭，排除其他因素后，结合同类药物致心力衰竭报告，考虑伏美替尼引起心力衰竭可能。患者经伏美替尼减量和抗心衰治疗后好转。结论 伏美替尼治疗可引起心力衰竭，临床应用时注意监测心脏彩超，以尽早识别和处置。更多还原

【Abstract】 Objective To investigate the clinical characteristics, mechanism and treatment strategies of heart failure caused by furmonertinib mesilate tablets. Methods A case of heart failure caused by the third generation of epidermal growth factor receptor-tyrosine kinase inhibitor(furmonertinib) in a female patient with advanced lung cancer was summarized. The potential mechanism and treatment strategies were studied based on a literature review. Results The patient developed heart failure 3 months after administration of furmonertinib. Considering that similar medication had been reported to induce heart failure, furmonertinib was believed to have induced heart failure in this patient after other potential risks were ruled out. Her cardiac function improved after reduction of the dosage of furmonertinib and anti-heart failure therapy. Conclusion The use of furmonertinib can cause heart failure, so echocardiography should be monitored for early identification and management in clinical practice.更多还原